This is sounding a bit odd. JCR Pharmaceuticals developed Temcell themselves, it is not remestemcel-L rebranded.
JCR in the beginning were licensed by Osiris to continue developing, testing and using the product for the indication aGVHD, in Japan.
Mesoblast bought out the Osiris IP and that included the license JCR has. JCR continue to manufacture their Temcell mesenchymal cell line in Japan, now under license to Mesoblast.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-527
-
- There are more pages in this discussion • 321 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |